Skip to content

The long-term efficacy of sequential precision repetitive transcranial magnetic stimulation on motor symptoms in Parkinson's disease:A two-arm, parallel controlled trial

The long-term efficacy of sequential precision repetitive transcranial magnetic stimulation on motor symptoms in Parkinson's disease:A two-arm, parallel controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500110383
Enrollment
Unknown
Registered
2025-10-13
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

Sponsors

The First Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age >= 40 years; 2.Meet the diagnostic criteria for primary Parkinson's disease (MDS Parkinson's Disease Diagnostic Criteria (2015 Edition)); 3.No medication adjustment in the 4 weeks before and during each stimulation; 4.MDS-UPDRS III score >= 8 points, Hoehn-Yahr score 1-4 points; 5.Mini-Mental State Examination (MMSE) score >= 22 points, and be able to complete behavioral tests and transcranial magnetic stimulation treatment.

Exclusion criteria

Exclusion criteria: 1.Focal brain injury or severe leukoencephalopathy (Fazekas grade 3 or above) on previous head MRI/CT scans; 2.Various secondary Parkinson's syndromes (vascular Parkinson's syndrome, drug-induced Parkinson's syndrome, etc.); 3.Severe craniocerebral trauma, cranial surgery or deep brain stimulation treatment; 4.Ferromagnetic implants in the body, such as cochlear implants, cardiac pacemakers, etc.; 5.A history of epilepsy, unexplained loss of consciousness, or taking anticonvulsant drugs for epileptic seizures; 6.Diagnosed with neuropsychiatric diseases other than Parkinson's disease; 7.A history of drug abuse or drug use; 8.Participated in any clinical trial in the past 6 months; 9.Pregnant/lactating women or subjects (including men) who plan to have children within 6 months; 10.Other situations that the researchers consider unsuitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Multimodal fMRI related indicators;

Secondary

MeasureTime frame
MDS-UPDRS III improvement value;Biological tissue markers;

Countries

China

Contacts

Public ContactPanpan Hu

The First Affiliated Hospital of Anhui Medical University

hupanpan@ahmu.edu.cn+86 135 1560 2285

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026